JP2022541591A5 - - Google Patents
Info
- Publication number
- JP2022541591A5 JP2022541591A5 JP2022503919A JP2022503919A JP2022541591A5 JP 2022541591 A5 JP2022541591 A5 JP 2022541591A5 JP 2022503919 A JP2022503919 A JP 2022503919A JP 2022503919 A JP2022503919 A JP 2022503919A JP 2022541591 A5 JP2022541591 A5 JP 2022541591A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- months
- pharmaceutical composition
- cancer
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962877233P | 2019-07-22 | 2019-07-22 | |
| US62/877,233 | 2019-07-22 | ||
| US201962890498P | 2019-08-22 | 2019-08-22 | |
| US62/890,498 | 2019-08-22 | ||
| US202063003613P | 2020-04-01 | 2020-04-01 | |
| US63/003,613 | 2020-04-01 | ||
| US202063031496P | 2020-05-28 | 2020-05-28 | |
| US63/031,496 | 2020-05-28 | ||
| PCT/US2020/042865 WO2021016233A1 (en) | 2019-07-22 | 2020-07-21 | Humanized anti-liv1 antibodies for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022541591A JP2022541591A (ja) | 2022-09-26 |
| JP2022541591A5 true JP2022541591A5 (enExample) | 2023-07-31 |
Family
ID=71995150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022503919A Pending JP2022541591A (ja) | 2019-07-22 | 2020-07-21 | がんの処置のためのヒト化抗ｌｉｖ１抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210030885A1 (enExample) |
| EP (1) | EP4004046A1 (enExample) |
| JP (1) | JP2022541591A (enExample) |
| KR (1) | KR20220035486A (enExample) |
| CN (1) | CN114423464A (enExample) |
| AU (1) | AU2020318975A1 (enExample) |
| BR (1) | BR112022001045A2 (enExample) |
| CA (1) | CA3147750A1 (enExample) |
| IL (1) | IL289842A (enExample) |
| MX (1) | MX2022000853A (enExample) |
| TW (1) | TW202116810A (enExample) |
| WO (1) | WO2021016233A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3213636A1 (en) | 2021-03-18 | 2022-09-22 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| WO2024165056A1 (en) * | 2023-02-07 | 2024-08-15 | LaNova Medicines Limited | Antibodies targeting liv-1 and uses thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025162207A1 (zh) * | 2024-01-31 | 2025-08-07 | 上海复宏汉霖生物技术股份有限公司 | 抗liv1抗体及使用方法 |
| CN120040587B (zh) * | 2025-04-27 | 2025-08-08 | 上海宏成药业有限公司 | 抗liv-1抗体或其抗原结合片段及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| FI102355B1 (fi) | 1988-02-11 | 1998-11-30 | Bristol Myers Squibb Co | Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi |
| ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| EP0871490B1 (en) | 1995-12-22 | 2003-03-19 | Bristol-Myers Squibb Company | Branched hydrazone linkers |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| ES2544527T3 (es) | 2002-07-31 | 2015-09-01 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
| WO2004067564A2 (en) | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions against cancer antigen liv-1 and uses thereof |
| EP3434275A1 (en) | 2003-11-06 | 2019-01-30 | Seattle Genetics, Inc. | Assay for cancer cells based on the use of auristatin conjugates with antibodies |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| JP5171621B2 (ja) | 2005-07-07 | 2013-03-27 | シアトル ジェネティックス， インコーポレイテッド | フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物 |
| WO2009052431A2 (en) | 2007-10-19 | 2009-04-23 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
| EP3786185A1 (en) * | 2010-12-06 | 2021-03-03 | Seagen Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
| WO2017202744A1 (en) * | 2016-05-26 | 2017-11-30 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for cancer treatment |
| JP6695003B2 (ja) * | 2016-09-26 | 2020-05-20 | イムクローン・リミテッド・ライアビリティ・カンパニーＩｍｃｌｏｎｅ ＬＬＣ | 癌のための併用療法 |
| MX2020005640A (es) * | 2017-12-01 | 2020-08-20 | Seattle Genetics Inc | Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama. |
-
2020
- 2020-07-21 CA CA3147750A patent/CA3147750A1/en active Pending
- 2020-07-21 BR BR112022001045A patent/BR112022001045A2/pt unknown
- 2020-07-21 EP EP20753613.7A patent/EP4004046A1/en not_active Withdrawn
- 2020-07-21 TW TW109124627A patent/TW202116810A/zh unknown
- 2020-07-21 WO PCT/US2020/042865 patent/WO2021016233A1/en not_active Ceased
- 2020-07-21 MX MX2022000853A patent/MX2022000853A/es unknown
- 2020-07-21 CN CN202080066262.1A patent/CN114423464A/zh active Pending
- 2020-07-21 JP JP2022503919A patent/JP2022541591A/ja active Pending
- 2020-07-21 US US16/934,745 patent/US20210030885A1/en not_active Abandoned
- 2020-07-21 AU AU2020318975A patent/AU2020318975A1/en not_active Abandoned
- 2020-07-21 KR KR1020227005740A patent/KR20220035486A/ko not_active Abandoned
-
2022
- 2022-01-13 IL IL289842A patent/IL289842A/en unknown
-
2023
- 2023-02-17 US US18/171,208 patent/US20230330241A1/en not_active Abandoned